Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
12,219 total articles
Yeleswaram Krishnaswamy, Chief Development Officer of Rapport Therapeutics, sold 20,225 shares on April 17, 2026, for $808,844 under a pre-existing Rule 10b5-1 plan. The stock traded between $39.90 and $40.38 on the day of the sale and is currently at $36.95. Separately, the company reported strong Phase 2a results for RAP-219 and announced plans t…
Anang K. Majmudar, Senior Vice-President of General American Investors Co Inc (NYSE:GAM), purchased 500 shares of the firm’s 5.95% Preferred Stock on April 20, 2026 for $24.66 per share, a $12,330 transaction. The purchase raises his direct preferred-stock holding to 12,000 shares. The Form 4 reporting the trade was filed with the Securities and Ex…
Amazon Chief Executive Andrew R. Jassy sold 31,000 shares of Amazon common stock on April 17, 2026, in a transaction totaling $7,905,000 at $255.00 per share. The sale, completed under a Rule 10b5-1 trading plan adopted November 14, 2025, occurred while the stock traded close to a 52-week high and in the context of several company initiatives and a…
Kevin J. Khanna, an executive vice president at Fifth Third Bancorp, sold 6,000 shares of the bank's common stock on April 20, 2026, generating $304,630 at prices between $50.77 and $50.775 per share. After the transaction he holds 76,299 shares. The stock trades at $51.08, up 58% over the past year. Separately, Fifth Third reported Q1 2026 results…
Kurtis Joseph Binder, chief financial officer of Arlo Technologies, sold 25,000 shares of the company’s common stock on April 17, 2026, generating proceeds of $379,857. The transaction was carried out under a Rule 10b5-1 plan adopted in November 2025. Following the sale, Binder directly holds 564,885 shares. The sale comes against a backdrop of str…
Alejandro Perez, Senior Executive Vice President at Bank of New York Mellon Corp (BK), sold 12,504 shares on April 17, 2026, for about $1,713,155 and gifted 1,000 shares to a charitable donor-advised fund. After the transactions, Perez holds 62,612.7610 shares directly and 1,806.0786 shares indirectly in a 401(k). Analysts have raised price targets…
Phreesia Inc.'s general counsel, Allison C. Hoffman, disposed of 6,176 shares of the company's common stock on April 20, 2026, under a Rule 10b5-1 trading plan adopted in December 2025. The sale totaled $55,954. The filing arrives as Phreesia reported slightly better-than-expected fourth-quarter fiscal 2026 revenue and adjusted EBITDA, but the comp…
Kerry Wentworth, Nuvation Bio's Chief Regulatory Officer, sold 36,750 shares of Class A common stock on April 17, 2026 under a 10b5-1 trading plan. The transactions followed an option exercise and leave her holding 53,000 direct shares and 215,250 options. The disclosures arrive alongside corporate developments including an amended license agreemen…
Kurtis R. Kurimsky, corporate controller at Bank of New York Mellon Corp, sold 5,290 shares on April 17, 2026, for $719,523. The disposal occurred at a weighted average price of $136.0157 per share and left Kurimsky with 17,259 shares held directly. The transaction comes as BK shares trade close to a 52-week high and follows a quarter that prompted…
J. Kevin McCarthy, Senior Executive Vice President and General Counsel at Bank of New York Mellon Corp, sold 30,000 shares on April 17, 2026, totaling $4,094,919. The transaction took place while the stock traded close to its 52-week high and follows several analyst price-target increases after a strong first-quarter showing.
Adam Eltoukhy, Samsara Inc.'s Executive Vice President, Chief Legal Officer and Secretary, sold 5,473 shares of Class A common stock on April 20, 2026, for a total of $167,906 under a Rule 10b5-1 trading plan adopted March 28, 2025. The transactions consisted of multiple lots, including 5,373 shares at a weighted-average price of $30.6696 and 100 s…
W. Nicholas Howley, a TransDigm Group director, sold 10,132 shares through his family trust on April 20, 2026, generating roughly $12.8 million after exercising options for the same number of shares. The transactions leave the trust holding 21,547.513 shares. The company has reported preliminary quarterly results, completed multiple acquisitions, a…
Yvonne Hui, Principal Accounting Officer at Phreesia, Inc. (NASDAQ: PHR), sold 1,327 shares of company common stock on April 17, 2026, for $9.28 per share, generating $12,314 in proceeds. The filing shows Hui now directly holds 24,664 shares. The transaction was executed under a Rule 10b5-1 trading plan adopted January 15, 2026. The insider move co…
Equitable Holdings CEO Mark Pearson sold 39,700 shares under a pre-established Rule 10b5-1 plan on April 20, 2026, for about $1.65 million and exercised options to acquire 27,200 shares at $23.18 each. The transactions leave Pearson with 789,183.2978 shares. The stock trades at $41 with an $11.5 billion market cap amid mixed financial signals inclu…
Malik Fady Ibraham, executive vice president for research and development at Cytokinetics Inc. (NASDAQ: CYTK), sold 3,500 shares of company stock on April 21, 2026 for $65.69 per share, netting $229,915. The sale came after Dr. Malik exercised an equal number of non-qualified stock options at $7.80 per share. Following these moves, he holds 153,902…
Hallie E. Kuhn, Executive Vice President of Capital Markets and Co-Lead of Life Science at Alexandria Real Estate Equities, Inc. (NASDAQ: ARE), sold 536 shares of the company on April 17, 2026, realizing $25,835. The stock has recovered 7.9% over the past week after a six-month decline of 34% and currently trades near $47.81. Alexandria declared a …
Julie Lodge-Jarrett, Executive Vice President and Chief People & Purpose Officer at DICK'S Sporting Goods (DKS), reported the sale of common stock totaling $925,523 on April 17, 2026, while also exercising options that resulted in the acquisition of 4,140 shares the same day. The transactions were disclosed in a Form 4 filed April 21, 2026. Several…
Phillip John Riese, a Remitly Global, Inc. director, sold 40,000 shares on April 17, 2026, under a Rule 10b5-1 plan adopted March 11, 2025, generating $801,600 at $20.04 per share. The transaction followed option exercises and leaves Riese with 122,496 directly held shares and 440,000 derivative shares. The sale coincides with Remitly stock strengt…
Michael Frederick Klein, Executive Vice President and President of Personal Insurance at The Travelers Companies, Inc. (TRV), sold 10,000 shares of Travelers common stock on April 20, 2026, for $3,037,690 after exercising options to acquire the same number of shares earlier that day. The transactions and the insurer's recent first-quarter 2025 resu…
Stefan A. Dyckerhoff, a director at Astera Labs Inc. (NASDAQ: ALAB), sold 24,998 shares of common stock on April 17 and April 20, 2026, under a Rule 10b5-1 trading arrangement adopted December 1, 2025. The disposals amounted to $4,376,257 at prices between $175.00 and $175.51 per share. The transactions occurred as ALAB shares have risen 223% over …
Dirk Kersten, through an entity he is affiliated with, recorded the sale of 337,248 shares of Dyne Therapeutics (NASDAQ:DYN) in two transactions on April 17 and April 20, 2026, generating roughly $6.82 million. The disposals were carried out indirectly by ForDyne B.V. under a Rule 10b5-1 trading plan adopted in November 2025. The filings also show …
RCM Technologies Chief Financial Officer Kevin D. Miller sold 5,385 shares of company stock in two trades in April 2026, generating proceeds of $172,367. The sales were executed under a nondiscretionary 10b5-1 plan established in August 2024. The stock has climbed 86% over the past year and is trading close to its 52-week high.
Jabil Inc. COO Andrew Priestley sold 3,169 shares on April 20, 2026, generating $1,045,770 in proceeds and leaving him with 57,098 directly held shares. The insider sale coincides with the company reporting strong second-quarter fiscal 2026 results and several analyst price-target changes, while market data indicates the stock has outperformed over…
Saiyed Atiq Raza, a director of Arteris, Inc. (NASDAQ: AIP), sold roughly $1.99 million in company shares across two trades on April 17 and April 20, 2026, under a 10b5-1 plan adopted November 7, 2025. The sales were executed via a revocable trust for which Mr. Raza serves as trustee. The disclosure comes as the stock trades near its 52-week high a…
Jeffrey P. Klenk, Executive Vice President and President of Bond & Specialty Insurance at Travelers Companies, sold 6,413.654 shares of common stock on April 20, 2026, generating $1,956,549 at $305.06 per share. The sale was disclosed in an SEC filing dated April 21, 2026. After the transaction, Klenk retains direct ownership of 6,075.303 shares. T…
